These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 10523087)

  • 1. The end of the heparin pump? Low molecular weight heparins have practical advantages, but clinical advantages are small.
    Stein K; Nicholson T
    BMJ; 1999 Aug; 319(7209):576. PubMed ID: 10523087
    [No Abstract]   [Full Text] [Related]  

  • 2. Current and potential uses of low molecular weight heparin: a review and an economic analysis.
    Seo P; Locke CF
    Am J Manag Care; 2000 Apr; 6(4):498-506; quiz 507-8. PubMed ID: 10977456
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LMW heparins: from transition to fruition.
    Check W
    CAP Today; 1999 Jun; 13(6):1, 62, 66-7; passim. PubMed ID: 10539128
    [No Abstract]   [Full Text] [Related]  

  • 4. Low-molecular-weight heparins.
    Weitz JI
    N Engl J Med; 1997 Sep; 337(10):688-98. PubMed ID: 9278467
    [No Abstract]   [Full Text] [Related]  

  • 5. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
    Ottani F; Ferrini D; Di Pasquale G; Galvani M
    Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic evaluation of the use of enoxaparin in non-ST-elevation acute coronary syndrome.
    Nutescu EA; Steinmetz Pater K
    Expert Opin Pharmacother; 2008 Jan; 9(1):95-105. PubMed ID: 18076341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trials of low-molecular-weight heparins in cardiology.
    Spinler SA
    Pharmacotherapy; 1999 Sep; 19(9 Pt 2):147S-154S. PubMed ID: 10610005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical application of enoxaparin.
    Hofmann T
    Expert Rev Cardiovasc Ther; 2004 May; 2(3):321-37. PubMed ID: 15151480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost implications of low molecular weight heparins as prophylaxis following total hip and knee replacement.
    Bell GK; Goldhaber SZ
    Vasc Med; 2001; 6(1):23-9. PubMed ID: 11358156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
    Holzheimer RG
    Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prophylaxis of postoperative thromboembolism. New alternatives to low-molecular-weight heparin].
    Bergqvist D; Siegbahn A
    Lakartidningen; 2002 Jul; 99(28-29):3039-41. PubMed ID: 12170516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronically anticoagulated patients who need surgery: can low-molecular-weight heparins really be used to "bridge" patients instead of intravenous unfractionated heparin?
    Jaff MR
    Catheter Cardiovasc Interv; 2009 Jul; 74 Suppl 1():S17-21. PubMed ID: 19213061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-fractionated heparin versus low molecular weight heparin in acute coronary syndromes].
    González Pacheco H
    Arch Cardiol Mex; 2001; 71 Suppl 1():S63-8. PubMed ID: 11565348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-molecular weight heparin as prophylaxis against thromboembolism after total hip replacement--is it worth the price?
    Persson BM
    Acta Orthop Scand; 2000 Apr; 71(2):215-6. PubMed ID: 10852334
    [No Abstract]   [Full Text] [Related]  

  • 15. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
    Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
    Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of low-molecular-weight heparins in non-ST-segment elevation acute coronary syndromes.
    Nguyen-Ho P; Levine GN
    Panminerva Med; 2002 Jun; 44(2):115-22. PubMed ID: 12032429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost comparison of at-home treatment of deep venous thrombosis with low molecular weight heparin to inpatient treatment with unfractionated heparin.
    Smith BJ; Weekley JS; Pilotto L; Howe T; Beven R
    Intern Med J; 2002; 32(1-2):29-34. PubMed ID: 11783670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-molecular-weight heparin for initial treatment of venous thromboembolism.
    Brewer D
    Am Fam Physician; 2005 Jul; 72(1):75-6. PubMed ID: 16035683
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost analysis of "bridging therapy" with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation.
    Amorosi SL; Tsilimingras K; Thompson D; Fanikos J; Weinstein MC; Goldhaber SZ
    Am J Cardiol; 2004 Feb; 93(4):509-11. PubMed ID: 14969639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and economic impact of low-molecular weight heparins in managed care. Introduction.
    Am J Manag Care; 2000 Nov; 6(20 Suppl):S1024-5. PubMed ID: 11484301
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.